Jan Skvarka - Net Worth and Insider Trading
Jan Skvarka Net Worth
The estimated net worth of Jan Skvarka is at least $541,102 dollars as of 2024-05-24. Jan Skvarka is the Director of Zentalis Pharmaceuticals Inc and owns about 47,970 shares of Zentalis Pharmaceuticals Inc (ZNTL) stock worth over $541,102. Jan Skvarka is also the President and CEO of Trillium Therapeutics Inc and owns about 0 shares of Trillium Therapeutics Inc (TRIL) stock worth over $0. Details can be seen in Jan Skvarka's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Jan Skvarka has not made any transactions after 2023-09-11 and currently still holds the listed stock(s).
Transaction Summary of Jan Skvarka
Jan Skvarka Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Jan Skvarka owns 2 companies in total, including Zentalis Pharmaceuticals Inc (ZNTL) , and Monte Rosa Therapeutics Inc (GLUE) .
Click here to see the complete history of Jan Skvarka’s form 4 insider trades.
Insider Ownership Summary of Jan Skvarka
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| ZNTL | Zentalis Pharmaceuticals Inc | 2023-09-11 | director |
| GLUE | Monte Rosa Therapeutics Inc | 2023-03-23 | director |
Jan Skvarka Latest Holdings Summary
Jan Skvarka currently owns a total of 2 stocks. Among these stocks, Jan Skvarka owns 47,970 shares of Zentalis Pharmaceuticals Inc (ZNTL) as of September 11, 2023, with a value of $541,102 and a weighting of 100%. Jan Skvarka also owns 0 shares of Trillium Therapeutics Inc (TRIL) as of January 14, 2021, with a value of $0 and a weighting of 0%.
Latest Holdings of Jan Skvarka
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| ZNTL | Zentalis Pharmaceuticals Inc | 2023-09-11 | 47,970 | 11.28 | 541,102 |
| TRIL | Trillium Therapeutics Inc | 2021-01-14 | 0 | 18.44 | 0 |
Holding Weightings of Jan Skvarka
Jan Skvarka Form 4 Trading Tracker
According to the SEC Form 4 filings, Jan Skvarka has made a total of 1 transactions in Zentalis Pharmaceuticals Inc (ZNTL) over the past 5 years, including 0 buys and 1 sells. The most-recent trade in Zentalis Pharmaceuticals Inc is the sale of 5,000 shares on September 11, 2023, which brought Jan Skvarka around $125,250.
According to the SEC Form 4 filings, Jan Skvarka has made a total of 1 transactions in Trillium Therapeutics Inc (TRIL) over the past 5 years, including 0 buys and 1 sells. The most-recent trade in Trillium Therapeutics Inc is the sale of 25,000 shares on January 14, 2021, which brought Jan Skvarka around $375,750.
Insider Trading History of Jan Skvarka
- 1
Jan Skvarka Trading Performance
Jan Skvarka Ownership Network
Jan Skvarka Owned Company Details
What does Zentalis Pharmaceuticals Inc do?
Who are the key executives at Zentalis Pharmaceuticals Inc?
Jan Skvarka is the director of Zentalis Pharmaceuticals Inc. Other key executives at Zentalis Pharmaceuticals Inc include Chief Financial Officer Melissa B, Epperly , General Counsel Andrea Paul , and Chief Medical Officer Carrie Brownstein .
Zentalis Pharmaceuticals Inc (ZNTL) Insider Trades Summary
Over the past 18 months, Jan Skvarka made 1 insider transaction in Zentalis Pharmaceuticals Inc (ZNTL) with a net sale of 5,000. Other recent insider transactions involving Zentalis Pharmaceuticals Inc (ZNTL) include a net sale of 82,326 shares made by Cam Gallagher , a net sale of 24,575 shares made by Melissa B, Epperly , and a net sale of 96,375 shares made by Kevin D. Bunker .
In summary, during the past 3 months, insiders sold 3,356 shares of Zentalis Pharmaceuticals Inc (ZNTL) in total and bought 0 shares, with a net sale of 3,356 shares. During the past 18 months, 227,155 shares of Zentalis Pharmaceuticals Inc (ZNTL) were sold and 22,000 shares were bought by its insiders, resulting in a net sale of 205,155 shares.
Zentalis Pharmaceuticals Inc (ZNTL)'s detailed insider trading history can be found in Insider Trading Tracker table.
Zentalis Pharmaceuticals Inc Insider Transactions
Jan Skvarka Mailing Address
Above is the net worth, insider trading, and ownership report for Jan Skvarka. You might contact Jan Skvarka via mailing address: C/o Trillium Therapeutics Inc., 2488 Dunwin Drive, Mississauga A6 L5l 1j9.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
